###### Key messages

A Body Shape Index (ABSI) was significantly and positively correlated with visceral fat area, independently of body mass index.Patients with high ABSI were significantly older, with more female predominance, had lower urinary C peptide, longer duration of diabetes, severe diabetic microvascular complications and higher pulse wave velocity (PWV) than those with low ABSI.In multivariate linear regression analysis, ABSI remained independently associated with PWV.

Introduction {#s1}
============

Obesity, especially visceral obesity, has been reported to be associated with insulin resistance, dyslipidemia, and hypertension, thus increasing the risk for cardiovascular disease (CVD).[@R1] Abdominal visceral fat has been strongly associated with cardiovascular risks.[@R5] [@R6] However, a direct measure of visceral fat is limited due to the high cost of imaging procedures such as CT or MRI. On the other hand, several indirect measures of (visceral) adiposity have been developed so far.

Body mass index (BMI) has long been used as a surrogate marker for excess body fat, but its inability to discriminate between fat and lean mass may limit its use to estimate visceral adiposity.[@R7] Waist circumference (WC) and waist-to-hip ratio (WHR) have alternatively been used as surrogate markers for abdominal obesity and the association of these markers with insulin resistance has been reported to be better than that of BMI.[@R10] [@R11] While WC is more strongly associated with CVD than BMI,[@R10]the J-curve association is observed between BMI or WC and mortality.[@R12] In addition, the strong correlation between WC and BMI implies that the impact of WC on cardiometabolic risks could be confounded with BMI as are other measures including WHR. A large European cohort study[@R15] showed a strong linear association between WC and death after adjusting for BMI, suggesting that both general adiposity (ie, BMI) and visceral abdominal adiposity (ie, WC adjusted for BMI) should be simultaneously determined for estimating the risk of death. Eventually, the development of new anthropometric measures has emerged to efficiently estimate both visceral abdominal and general adiposities and precisely predict mortality and cardiovascular events.

In 2012, Krakauer and Krakauer[@R12] have proposed a new anthropometric measure (A Body Shape Index, ABSI), which in conjunction with BMI can estimate both visceral abdominal and general overall adiposities. It is important that ABSI is not confounded with BMI (ie, ABSI has been developed to be independent of BMI) for the assessment of abdominal obesity. ABSI, which is adjusted for WC, BMI and height, was able to better predict mortality than WC and BMI in the National Health and Nutrition Examination Survey IV (NHANES IV) population (it is a multiethnic reflecting population in the USA).[@R12] Recent studies also demonstrated that ABSI is a robust predictor of all-cause mortality.[@R13] [@R16] The largest study from Europe reported that the combination of ABSI and BMI could predict risk for CVD events better than any of the single measures for body composition such as BMI or WC.[@R17] Considering the findings in the studies,[@R12] [@R13] [@R16] [@R17] it is of importance that ABSI demonstrates a positive linear relationship with all-cause or cardiovascular mortality, whereas BMI and WC show the J-shaped associations.[@R14] Among patients with diabetes, it is unknown whether ABSI is associated with mortality or cardiovascular events.

Arterial stiffness is a strong predictor of CVD and mortality in the diabetic population,[@R18] [@R19] and we and others recently reported that increased visceral fat accumulation is associated with arterial stiffness and carotid atherosclerosis, regardless of BMI in patients with diabetes.[@R20] [@R21] However, little is known regarding the association of ABSI with adiposity and cardiovascular risks in individuals with diabetes. This study was designed to investigate whether ABSI could be associated with arterial stiffness in patients with type 2 diabetes.

Methods {#s2}
=======

Participants {#s2a}
------------

Patients with type 2 diabetes who were admitted to Tokyo Medical and Dental University Hospital for the purpose of glycemic control and/or evaluation of diabetic complications participated in this study. Patients were eligible if they were aged ≥20 years; 607 patients who measured both brachial-ankle pulse wave velocity (baPWV) and visceral fat area (VFA) and subcutaneous fat area (SFA) with a dual bioelectrical impedance analyzer were enrolled. Patients with severe renal impairment (estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73 m^2^ or undergoing renal replacement therapy), pregnant women and those with infectious or malignant diseases were excluded. Type 2 diabetes was diagnosed according to the criteria of the Japan Diabetes Society (JDS).[@R22] This study complies with the principles laid by the Declaration of Helsinki and has been approved by the ethical committee of Tokyo Medical and Dental University (number 1924).

Clinical and biochemical analysis {#s2b}
---------------------------------

Standardized questionnaires were used to obtain information on smoking, medication, and history. Smoking history was classified as either current smoker or non-smoker. CVD was defined as the presence of a previous stroke, myocardial infarction, or coronary revascularization procedure. Glycated hemoglobin (HbA1c) was measured by the latex agglutination method. HbA1c levels were expressed in accordance with the National Glycohemoglobin Standardization Programs recommended by the Japanese Diabetes Society.[@R22] Urinary albumin and creatinine excretion were measured by the turbidimetric immunoassay and enzymatic method, respectively, in a single 24 h urine collection. Glomerular filtration rate (GFR) was estimated using the Japanese equation with serum creatinine (mg/dL)[@R23]; GFR=194× SCr^−1.094^× age^−0.287^ ((if female)×0.739), where SCr stands for serum creatinine in mg⁄dL, measured by an enzymatic method. Coefficient of variation of R-R intervals (CV-RR) was used for the assessment of diabetic neuropathy. Height was measured to the nearest 0.1 cm without shoes using a stadiometer. Weight was measured in light clothing without shoes using a standard scale and recorded to the nearest 0.1 kg. We measured WC at the umbilical level in minimal respiration in a standing position. BMI was calculated as weight divided by the square of height (kg/m^2^). ABSI was calculated by the following formula: ABSI=WC/BMI^2/3^×height^1/2^.[@R12] VFA and SFA were measured at the level of the umbilicus with a dual bioelectrical impedance analyzer (DUALSCAN, Omron Healthcare Co, Kyoto, Japan).[@R20] The baPWV was measured using a volume-plethysmographic apparatus (BP-203RPE II form PWV/ABI, Omron Healthcare Co, Kyoto, Japan), with participants in the supine position after at least 5 min of rest.[@R24] [@R25] baPWV was calculated as reported previously.[@R26] We simultaneously measured baPWV on both the right and left sides and the averaged values from each individual were subjected to statistical analysis.

Statistical analysis {#s2c}
--------------------

Statistical analysis was performed using programs available in the SPSS V.21.0 statistical package (SPSS Inc, Chicago, Illinois, USA). Data are presented as mean±SD or geometric mean with 95% CI as appropriate according to data distribution. Differences among the four groups were tested with a one-way analysis of variance (ANOVA) (continuous variables) or χ^2^ test (categorical variables). Linear regression analyzes with a stepwise procedure were used to assess the cross-sectional association of markers for adiposity including ABSI, BMI, WC, VFA, SFA, and VFA/SFA (V/S) ratio with baPWV. In addition, the correlation of z-scores for these measures was determined as reported previously.[@R12] The following covariates were incorporated into the analysis: age, gender, duration of diabetes, smoking status, systolic blood pressure, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, HbA1c, urinary albumin excretion, eGFR, the presence of proliferative diabetic retinopathy and the use of insulin, calcium channel blockers, ACE inhibitors, angiotensin receptor blockers, statins, and antiplatelet agents. Differences were considered to be statistically significant at a p value \<0.05.

Results {#s3}
=======

Clinical characteristics according to ABSI quartiles {#s3a}
----------------------------------------------------

A total of 607 Japanese patients with type 2 diabetes (mean age 64±12 years; 40.0% female) were enrolled in this study. [Table 1](#BMJDRC2015000188TB1){ref-type="table"} shows the clinical characteristics according to the ABSI quartiles among patients with type 2 diabetes. There were significant differences in age, gender, urinary C peptide, duration of diabetes, albuminuria, CV-RR, and baPWV levels among patients. Patients with high ABSI were significantly older, with more female predominance, had lower urinary C peptide, a longer duration of diabetes, lower CV-RR, and higher baPWV than those with low ABSI. As shown in [figure 1](#BMJDRC2015000188F1){ref-type="fig"}, modest increases in VFA, SFA, and WC were observed in parallel with the increase in ABSI among patients with type 2 diabetes. Patients with high ABSI tended to have low BMI compared with those with low ABSI, but the association between ABSI and BMI did not reach statistical significance ([figure 1](#BMJDRC2015000188F1){ref-type="fig"}).

###### 

Clinical characteristics according to ABSI quartiles in patients with type 2 diabetes

                               ABSI Q1   (N=153)          ABSI Q2   (N=151)          ABSI Q3   (N=151)          ABSI Q4   (N=152)          p Value\*
  ---------------------------- --------- ---------------- --------- ---------------- --------- ---------------- --------- ---------------- -----------
  Age (years)                  59        \(13\)           63        \(11\)           65        \(12\)           69        \(12\)           \<0.001
  Gender (% male)              62                         70                         62                         45                         0.001
  SBP (mm Hg)                  129       \(19\)           132       \(18\)           128       \(17\)           131       \(20\)           0.216
  DBP (mm Hg)                  76        \(12\)           77        \(13\)           76        \(11\)           74        \(12\)           0.403
  HbA1c (mmol/L)               72.8      (21.4)           72.2      (19.3)           76.0      (19.4)           72.1      (19.5)           0.410
  HbA1c (%)                    8.8       (2.0)            8.7       (1.8)            9.0       (2.0)            8.8       (1.9)            
  HDL-C (mmol/L)               1.25      (0.41)           1.24      (0.33)           1.23      (0.39)           1.31      (0.34)           0.252
  LDL-C (mmol/L)               2.91      (0.91)           3.03      (1.02)           2.82      (0.78)           2.94      (0.86)           0.238
  Triglycerides (mmol/L)       1.45      (1.10 to 1.81)   1.47      (1.16 to 1.77)   1.51      (1.08 to 1.99)   1.45      (1.32 to 1.56)   0.613
  Urinary C peptide (μg/day)   47.1      (42.9 to 51.4)   48.4      (44.7 to 52.0)   45.8      (41.6 to 50.0)   33.9      (30.8 to 37.0)   0.001
  DM duration (years)          12        \(10\)           12        \(10\)           12        \(9\)            15        \(10\)           0.044
  Urinary albumin (mg/day)     28.5      (15 to 42)       27.7      (19 to 37)       17.6      (16 to 19)       20.9      (12 to 30)       0.014
  eGFR (mL/min/1.73 m^2^)      73.6      (24.8)           72.0      (24.5)           70.4      (23.8)           70.9      (28.9)           0.691
  PDR (%)                      12                         12                         14                         15                         0.726
  CV-RR (%)                    4.3       (2.4)            4.2       (2.3)            3.8       (2.3)            3.3       (2.0)            0.003
  baPWV (cm/s)                 1611      \(349\)          1702      \(520\)          1713      \(356\)          1806      \(393\)          0.001
  History of CVD (%)           14                         14                         15                         16                         0.946

Data are expressed as mean (SD), geometric mean (95% CI) or percentage as appropriate.

\*ANOVA or χ^2^ test.

ABSI, A Body Shape Index; ANOVA, analysis of variance; baPWV, brachial-ankle pulse wave velocity; CVD, cardiovascular disease; CV-RR, coefficient of variation of R-R intervals; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PDR, proliferative diabetic retinopathy; SBP, systolic blood pressure.

![Visceral fat area (VFA, cm^2^), subcutaneous fat area (SFA, cm^2^), body mass index (BMI, kg/m^2^) and waist circumference (WC, cm) levels according to the quartiles of A Body Shape Index (ABSI) in patients with type 2 diabetes. p Values by one-way analysis of variance (ANOVA).](bmjdrc2015000188f01){#BMJDRC2015000188F1}

Correlation among markers for body composition and baPWV {#s3b}
--------------------------------------------------------

[Table 2](#BMJDRC2015000188TB2){ref-type="table"} shows the correlation among anthropometric markers for body composition (height, weight, BMI, WC and ABSI), direct measures of visceral and subcutaneous fat (VFA and SFA), and baPWV. ABSI was modestly correlated with WC (r=0.391, p\<0.001), VFA (r=0.138, p=0.001) and SFA (r=0.161, p\<0.001). In contrast, ABSI was negatively correlated to weight (r=−0.155, p\<0.001) and BMI (r=−0.085, p=0.037). We further determined whether the correlation between these markers could be observed after adjusting for age and gender using z-scores for these measures of adiposity. The correlation between z-score for ABSI and VFA was statistically significant (r=0.170, p\<0.001); however, z-score for ABSI was not associated with z-score for BMI at all (r=0.009, p=0.820).

###### 

Correlations among markers for body composition

              Height    Weight    BMI       WC        VFA       SFA       ABSI
  ----------- --------- --------- --------- --------- --------- --------- ---------
  *r*                                                                     
  Height      1         0.543     0.026     0.150     0.094     0.086     −0.177
  Weight      0.455     1         0.848     0.797     0.716     0.762     −0.155
  BMI         −0.095    −0.015    1         0.855     0.795     0.846     −0.085
  WC          0.089     0.814     0.852     1         0.803     0.856     0.391
  VFA         0.050     0.771     0.771     0.763     1         0.753     0.138
  SFA         −0.003    0.711     0.790     0.800     0.780     1         0.161
  ABSI        −0.073    −0.015    0.009     0.482     0.170     0.226     1
  *p Value*                                                               
  Height      NA        \<0.001   0.501     \<0.001   0.018     0.030     \<0.001
  Weight      \<0.001   NA        \<0.001   \<0.001   \<0.001   \<0.001   \<0.001
  BMI         0.019     \<0.001   NA        \<0.001   \<0.001   \<0.001   0.037
  WC          0.029     \<0.001   \<0.001   NA        \<0.001   \<0.001   \<0.001
  VFA         0.216     \<0.001   \<0.001   \<0.001   NA        \<0.001   0.001
  SFA         0.947     \<0.001   \<0.001   \<0.001   \<0.001   NA        \<0.001
  ABSI        0.070     0.710     0.820     \<0.001   \<0.001   \<0.001   NA

Right side (above diagonal) shows correlations of the raw values; left side (below diagonal) shows correlations of the z-scores relative to age-specific and sex-specific means.

ABSI, A Body Shape Index; BMI, body mass index; NA, not applicable; SFA, subcutaneous fat area; VFA, visceral fat area; WC, waist circumference.

Association between ABSI and baPWV {#s3c}
----------------------------------

[Table 3](#BMJDRC2015000188TB3){ref-type="table"} shows univariate and multivariate linear regression models to investigate the association of anthropometric markers and direct measures of visceral and subcutaneous fat with baPWV. ABSI was significantly and positively associated with increased risk for baPWV in a univariate model. After adjustment for covariates including age, gender, duration of diabetes, and diabetic complications such as nephropathy, ABSI remained to be associated with baPWV. Furthermore, the association between ABSI and baPWV was unchanged even when VFA or BMI was forced into the multivariate model (standardized β 0.101, p=0.047 and standardized β 0.119, p=0.023, respectively). Regarding the direct measurement of abdominal fat, SFA was negatively and V/S ratio was positively associated with baPWV. Finally, we underwent the sensitivity analysis in which patients treated with pioglitazone (N=13) were excluded. Finally, the statistical significance between ABSI and baPWV was unchanged (standardized β 0.107, p=0.041) in the multivariate analysis including age, gender, blood pressure, and diabetic complications and further adjustment for VFA did not attenuate the association (standardized β 0.118, p=0.024).

###### 

Linear regression analyzes to determine the impact of markers for body composition on baPWV in patients with type 2 diabetes

              Univariate             Multivariate   
  ----------- ------------ --------- -------------- -------
  ABSI        0.150        \<0.001   0.095          0.043
  WC          −0.138       0.010     −0.060         0.200
  BMI         −0.128       0.008     −0.151         0.001
  VFA         −0.086       0.100     −0.059         0.201
  SFA         −0.182       \<0.001   −0.087         0.045
  V/S ratio   0.149        0.004     0.109          0.042

ABSI, A Body Shape Index; baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; SFA, subcutaneous fat area; VFA, visceral fat area; V/S, VFA/SFA; WC, waist circumference.

Discussion {#s4}
==========

Arterial stiffness is considered to be one of the manifestations of atherosclerosis. It directly reflects the arterial elasticity rather than organic changes in arterial walls such as formation of atherogenic plaques. Increased arterial stiffness has been reported to be strongly associated with mortality and cardiovascular events in patients with diabetes.[@R18] [@R19] Therefore, evaluation of arterial stiffness is important to estimate the risk for cardiovascular events among individuals with diabetes. This study, for the first time, demonstrates that ABSI appears to be a substantial marker of arterial stiffening in patients with type 2 diabetes. High ABSI was strongly associated with aging, long duration of diabetes, and low insulin secretion, all of which might account for the association between ABSI and arterial stiffness. In addition, ABSI was modestly and positively correlated to visceral adiposity independently of BMI.

Several previous studies demonstrated the significant association of ABSI with mortality, incident hypertension, diabetes, and CVD.[@R12] [@R13] [@R16] [@R27] The strengths of ABSI include the combination of non-invasive measures (WC, height, and weight) and low cost. In this study, consistent with previous studies,[@R10] [@R11] WC was strongly correlated with BMI (r=0.855), whereas ABSI was significantly and positively associated with VFA, independently of BMI. These findings suggest that among indirect measures of abdominal adiposity, ABSI has a superiority due to its being independent of BMI, compared with other measures such as WC. In addition, ABSI was significantly associated with pulse wave velocity (PWV) in the multivariate model including BMI as a covariate. Surprisingly, the statistical significance of ABSI with baPWV was not attenuated even after adjusting for VFA, suggesting that the association between ABSI and arterial stiffness might be, at least in part, independent of visceral adiposity. ABSI is a more direct marker of abdominal adiposity than visceral adiposity, since external anthropometrics cannot readily distinguish visceral from subcutaneous fat. This is particularly relevant in the light of our finding that ABSI remained a significant predictor of arterial stiffness even after adjustment for visceral fat. The weak correlation between ABSI and VFA implies the underlying mechanisms other than visceral adiposity which could account for the association between high ABSI and increased arterial stiffness. One possible explanation is that ABSI may inversely reflect muscle mass. Direct evidence has recently been proposed regarding the inverse association between ABSI and fat-free mass[@R30]; ABSI was negatively, independently of BMI, associated with fat-free mass estimated by bioelectrical impedance analysis (BIA). In addition, ABSI was correlated positively with C reactive protein and negatively with the reciprocal of insulin, as an index of insulin sensitivity in men.[@R30] Also, we and others recently reported that increased visceral fat with normal weight or normal WC was associated with arterial stiffening[@R20] and carotid atherosclerosis.[@R21] Together, high ABSI might reflect low skeletal muscle mass with increased visceral abdominal adiposity, systemic microinflammation, and insulin resistance, presumably leading to progression of arterial stiffening, and ABSI could be an important complement to BMI when identifying patients with diabetes at risk for arterial stiffening.

Strengths and limitations {#s4a}
-------------------------

The strength of our study is that we directly measured VFA and SFA with a dual-impedance analyzer. Eventually, we were able to investigate to what extent ABSI could reflect fat distribution. In addition, this is the first study to show the association between ABSI and arterial stiffness. ABSI was initially developed to predict the risk of death[@R12]; therefore, it is conceivable that our findings expand the usefulness of ABSI from the prediction of death to risk-estimation of arterial stiffening. This study has a couple of limitations that should be mentioned. First, it is impossible to infer causality because of its cross-sectional design. Second, the population in this study was ethnically and socially homogeneous, because this study was hospital-based and all the patients were Japanese; therefore, generalization of our findings might be limited. It is to be elucidated whether ABSI could be associated with arterial stiffness in populations other than Japanese. Third, we were unable to obtain information on diet and exercise in this study. These lifestyle could affect the distribution of body fat and non-fat mass; thus, exercise and diet may be confounders regarding the association of ABSI with arterial stiffening. Fourth, we could not do the subanalyzes by gender to investigate the association of ABSI with arterial stiffness due to the sample size. Finally, it is to be elucidated whether reduction of ABSI would reduce PWV and cardiovascular events.

In summary, our data suggest that ABSI precisely reflects visceral adiposity independently of BMI and is a substantial marker of arterial stiffening in patients with type 2 diabetes.
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